About Chugai
Chugai’s mission is
to create innovative drugs
for the benefit of patients.
News ReleasesRSS
- Apr 30, 2024 CHMP Recommends EU Approval of Alecensa as an Adjuvant Treatment for Resected ALK-Positive Early-Stage Lung Cancer
- Apr 26, 2024 Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan
- Apr 24, 2024 Chugai Announces 2024 1st Quarter Results
- Apr 24, 2024 F. Hoffmann-La Roche Announces First Quarter Sales 2024
- Apr 19, 2024 Alecensa Approved by FDA as the First Adjuvant Treatment for People with ALK-Positive Early-Stage Non-Small Cell Lung Cancer